Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Higher Dose of Methotrexate Approved: Pfizer
August 17, 2012
- Teijin Pharma Obtains Approval for Bonalon Jelly
August 16, 2012
- Humira Can Be Used for RA Patients without Treatment History: Abbott, Eisai
August 16, 2012
- Eisai’s US Subsidiary Morphotek Opens New Antibody Production Plant
August 16, 2012
- AZ, Pfizer Enter into Agreement for OTC Nexium, Also Eyeing OTC Versions of Other AZ Products
August 16, 2012
- Additional Indication of Pancreatic Neuroendocrine Tumors Approved for Sutent: Pfizer
August 16, 2012
- Symbicort Approved for COPD: Astellas, AZ
August 16, 2012
- Sosei Discontinues Development of Neuropathic Pain Treatment SD118, Transfers Rights to Beijing Tide of China
August 16, 2012
- MRs Ranks 3rd in Number of Average Annual Holidays at 133 Days: Survey
August 15, 2012
- Otsuka HD to Discuss with FDA this Month Delay in Approving Aripiprazole Injection
August 15, 2012
- Differences in Concurrent-Use Indications for DPP-4 Inhibitors to Be Eliminated through Special Clinical Trials
August 15, 2012
- Seikagaku Wins US Patent Suit over Joint Function Improver
August 15, 2012
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…